PCM
JAZZ icon

Prelude Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Prelude Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,600
Closed -$1.39M – 1721
2017
Q1 		$1.39M Buy
+9,600
New +$1.25M 0.13% 178

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prelude Capital Management's JAZZ Position: Q1 2026 in Review

Prelude Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 7,036 shares — an estimated $1.2M sold.

Prelude Capital Management first reported a position in JAZZ in Q2 2013 and held it in 30 quarters. The position peaked at $4.72M in Q2 2018. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Prelude Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 7,036 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.2M.
  • Prelude Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • Prelude Capital Management's Jazz Pharmaceuticals position peaked at $4.72M in Q2 2018.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.